Search - tctmd.com

Displaying 341 - 360 of 454

Sort: Relevancy | Date

Presentation LAA 2014

Novel Anticoagulants

Presenter: Michael D. Ezekowitz

July 17, 2014

Presentation LAA 2014

Device-based LAA Closure 2014: From Indications to Worldwide Practice

Presenter: Saibal Kar

July 17, 2014

Presentation LAA 2014

Coumadin: The Gold Standard

Presenter: Daniel L Lustgarten

July 17, 2014

Presentation LAA 2014

AMPLATZER Cardiac Plug (ACP):Attributes and Basic Technique

Presenter: Reda Ibrahim

July 17, 2014

Presentation LAA 2014

The Coherex WAVECREST: LAA Occluder

Presenter: Gregg W. Stone

July 17, 2014

Presentation LAA 2014

Surgical Approaches to the LAA: Devices and Data

Presenter: Subhasis Chatterjee

July 17, 2014

Presentation LAA 2014

Rate vs Rhythm control

Presenter: Jayanthi (Jay) N. Koneru

July 17, 2014

Presentation LAA 2014

Novel LAA Closure Technologies on the Horizon

Presenter: Vivek Y. Reddy

July 17, 2014

Presentation LAA 2014

LAA Ligation Using the LARIATTM Suture Delivery Device: Basic Technique and Keys to a Successful Result

Presenter: Jayanthi (Jay) N. Koneru

July 17, 2014

Presentation LAA 2014

LAA Closure: The Device, Attribute and Basic Technique- The Watchman Device -

Presenter: Saibal Kar

July 17, 2014

Presentation LAA 2014

Endocardial vs_ Epicardial LAA Closure: Theoretical and Practical Considerations

Presenter: William A. Gray

July 17, 2014

Presentation LAA 2014

Electrical Approaches to AF Ablation: Acute & Sustained Success, Complications

Presenter: Vivek Y. Reddy

July 17, 2014

Presentation LAA 2014

AF Basics:Etiology, Prevalence & Risk of Stroke

Presenter: Shephal Doshi

July 17, 2014

News Daily News

PREVAIL Published: Watchman, Warfarin Show Comparable Stroke Protection in A-fib

July 03, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

Presentation Fellows 2014

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: William Gray

April 14, 2014

Presentation TCT 2013

LAA Exclusion for Patients with Atrial Fibrillation: Appropriate Indications, Concerns, and Unanswered Questions

Presenter: Reda Ibrahim

October 31, 2013

Presentation TCT 2013

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Presenter: Brian Whisenant

October 30, 2013

News Conference News TCT 2013

Debate Leaves Little Doubt of LAA Closure Efficacy in the Prevention of Stroke in AF Patients

October 30, 2013

Advertisement

Novel Anticoagulants

Device-based LAA Closure 2014: From Indications to Worldwide Practice

Coumadin: The Gold Standard

AMPLATZER Cardiac Plug (ACP):Attributes and Basic Technique

The Coherex WAVECREST: LAA Occluder

Surgical Approaches to the LAA: Devices and Data

Rate vs Rhythm control

Novel LAA Closure Technologies on the Horizon

LAA Ligation Using the LARIATTM Suture Delivery Device: Basic Technique and Keys to a Successful Result

LAA Closure: The Device, Attribute and Basic Technique- The Watchman Device -

Endocardial vs_ Epicardial LAA Closure: Theoretical and Practical Considerations

Electrical Approaches to AF Ablation: Acute & Sustained Success, Complications

AF Basics:Etiology, Prevalence & Risk of Stroke

PREVAIL Published: Watchman, Warfarin Show Comparable Stroke Protection in A-fib

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Benefit of LAA Closure Becomes Most Evident After 1 Year

LAA Closure for Nonvalvular Atrial Fibrillation

LAA Exclusion for Patients with Atrial Fibrillation: Appropriate Indications, Concerns, and Unanswered Questions

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Debate Leaves Little Doubt of LAA Closure Efficacy in the Prevention of Stroke in AF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content